Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism.

M Castro, R Carrillo, F García, P Sanz, I Ferrer, P Ruiz-Sala, A I Vega, L Ruíz Desviat, B Pérez, C Pérez-Cerdá, B Merinero, M Ugarte

Journal: Nucleosides, nucleotides & nucleic acids 2015;33(4-6):233-40

PMID: 24940674

Abstract

Purine and pyrimidine disorders represent a heterogeneous group with variable clinical symptoms and low prevalence rate. In the last thirteen years, we have studied urine/plasma specimens from about 1600 patients and we have identified 35 patients: eight patients with adenylosuccinate lyase deficiency, eight patients with hypoxanthine-guanine phosphoribosyltransferase deficiency, one patient with purine nucleoside phosphorylase deficiency, ten patients with xanthine dehydrogenase deficiency, six patients with molybdenum cofactor deficiency and two patients with dihydropyrimidine dehydrogenase deficiency. Despite low incidence of these diseases, our findings highlight the importance of including the purine and pyrimidine analysis in the selective screening for inborn errors of metabolism in specialized laboratories, where amino acid and organic acid disorders are simultaneously investigated.

Address: a Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) , Madrid , Spain.

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.